Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Cocktail & Poster Display session

134P - Doxorubicin and olaparib (OLA) synergism in high-grade serous ovarian (HGOC) and triple-negative breast cancer (TNBC) cell lines with olaparib-resistance

Date

04 Oct 2023

Session

Cocktail & Poster Display session

Presenters

Jose Alejandro Perez Fidalgo

Citation

Annals of Oncology (2023) 8 (suppl_1_S5): 1-55. 10.1016/esmoop/esmoop101646

Authors

J.A. Perez Fidalgo1, J.J. Martinez Pretel2, P. Sanchez-Serrano3, V. Heredia4, M. Mendiola5, A. Redondo Sanchez6, O. Burgues7, B. Pineda Merlo8

Author affiliations

  • 1 Dept. Medical Oncology, Hospital Clinico Universitario de Valencia, 46010 - Valencia/ES
  • 2 Medical Oncology, INCLIVA - Fundación Investigación del Hospital Clínico Universitario de Valencia, 46010 - Valencia/ES
  • 3 INCLIVA - Fundación Investigación del Hospital Clínico Universitario de Valencia, 46010 - Valencia/ES
  • 4 Translational Oncology Lab., Hospital Universitario La Paz, 28046 - Madrid/ES
  • 5 Hospital Universitario La Paz, 28046 - Madrid/ES
  • 6 Dept. Oncologia Medica, Hospital Universitario La Paz, 28046 - Madrid/ES
  • 7 University of Valencia, 46015 - Valencia/ES
  • 8 Physiology, University of Valencia, 46010 - Valencia/ES

Resources

This content is available to ESMO members and event participants.

Abstract 134P

Background

An important proportion of patients receiving PARPi will become resistant. Doxorubicin is one of the drugs used as standard of care in HGSOC becoming resistant to platinum. The ROLANDO trial showed an encouraging activiy in platinum-resistant HGSOC of the combinacion of OLA-Doxo. The aim of our study was to assess if doxorubicin and OLA are synergistic in both PARP-I sensibitve and PARPi- resistant models.

Methods

8 cell lines, 4 parental and 4 corresponding OLA resistant clonal lines were used. One triple-negative breast cancer (TNBC) line (MDA-MB-231) and 3 HGSOC OLA-sensitive cell lines (PEO1, Kuramochi and SKOV3) were acquired. We generated 4 OLA resistant cell lines (MDA-MB-231-R, Kuramochi-R, PEO1-R and SKOV3-R) by exposure to OLA. IC50 of OLA and doxorubicin and the combination of both (combo) were calculated in all 8 lines (sensitive and resistance). Synergism between both drugs was assessed with the Chou Talalay method for combination index (CI) at Fa50. BRCA status (mutation vs wild type (wt)) was assessed by NGS in every line.

Results

When compared with parental lines DOXO IC50 was statistically superior in resistant cell lines except in PEO1-R suggesting a potential cross-resistant between OLA and DOXO. DOXO + OLA were synergistic in both parental and OLA-resistant lines in MDA-MB-231, PEO1 and SKOV3, with Fa50 for resistant lines=0.41 and 0.38 and 0.67 respectively. However, in Kuramochi combo was not synergistic, with Fa 50=1.36. DNA damage assessed by H2AX was similar between combo and DOXO single agent in all parental and resistant lines. Table: 134P

MD231 MD231R PEO1 PEO1R Kura KuraR SKOV3 SKOV3R
BRCA mutation Wt Wt BRCA2 BRCA2 BRCA2 BRCA2 Wt Wt
DOXO IC50 (nM) 313.3 676.2 101.2 67.3 122.6 995.3 312.1 581.5
Chou Talalay (Fa 50) 0.5 0.41 0.44 0.38 1.36 0.97 0.25 0.67
.

Conclusions

Our in vitro models suggest that OLA-resistant cells have a cross-resistance to Doxo. However synergistic effect of OLA+DOXO is observed in most OLA-resistant cell lines except in kuramochi-R. Further analyses will confirm whether this combination might be a valuable strategy to overcome OLA-resistance.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

INCLIVA.

Funding

AstraZeneca.

Disclosure

J.A. Perez Fidalgo: Financial Interests, Personal, Invited Speaker: AstraZeneca, Clovis, GSK, PharmaMar, AstraZeneca, Artios Pharma; Financial Interests, Personal, Advisory Board: AstraZeneca, GSK, Clovis, PharmaMar, Roche, Abilify Pharma; Financial Interests, Personal, Full or part-time Employment, Associate Professor: University of Valencia; Financial Interests, Institutional, Research Grant: GSK, PharmaMar; Financial Interests, Institutional, Invited Speaker: Novartis, AstraZeneca; Financial Interests, Institutional, Funding: GSK; Non-Financial Interests, Personal, Project Lead, Coordinating PI Phase III trial in breast cancer: Novartis; Non-Financial Interests, Personal, Member, Member of the Early Drug Development working group: ENGOT; Non-Financial Interests, Personal, Leadership Role, Member of the Executive Committee and Head of the Scientific Committee: GEICO; Non-Financial Interests, Personal, Leadership Role, Member of the Executive Committee and co-coordinator of Uterine Sarcoma Group: GEIS; Non-Financial Interests, Personal, Leadership Role, Co-chair Phase 2 group: GCIG; Non-Financial Interests, Personal, Member: BIG; Non-Financial Interests, Personal, Member, Adolescent and Young Adults working group: SEOM.M. Mendiola: Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, MSD; Financial Interests, Personal, Invited Speaker: GSK; Financial Interests, Institutional, Research Grant: Eisai; Financial Interests, Personal, Research Grant: PharmaMar; Financial Interests, Personal, Other: Roche, Pfizer. A. Redondo Sanchez: Financial Interests, Personal, Invited Speaker: MSD, AstraZeneca, GSK, Clovis, PharmaMar; Financial Interests, Personal, Advisory Board: MSD, AstraZeneca, GSK, Clovis, PharmaMar; Financial Interests, Institutional, Invited Speaker: Roche, Eisai, PharmaMar. B. Pineda Merlo: Financial Interests, Institutional, Research Grant: AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.